Although clinical trials in cancer patients had indicated that the combination of HSP90 inhibitors with other drugs display acceptable toxicity levels [16, 17], our results showed that 17-AAG caused a remarkable reduction on PASMCs growth in normal condition, and the PCNA expression was decreased by 17-AAG in a control setting. This evidence concerns the gene HSP90AA1 and cancer.